Chronic Obstructive Pulmonary Disease

Goldman's Cecil Medicine: Twenty Fourth Edition

Volumn 1, Issue , 2012, Pages 537-544

  Niewoehner, Dennis E ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Minneapolis Veterans Affairs Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904370396     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1604-7.00088-9     Document Type: Chapter

References (22)

1. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2006, 142:233-239.
2. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
3. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
4. Calverley PM, Rabe KR, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009, 374:685-694.
5. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:2407-2416.
6. Cranston JM, Crockett A, Moss J, et al. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD001744.
7. Lacasse Y, Goldstein R, Lasserson TJ, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;4:CD003793.
8. National Emphysema Treatment Trial Research Group A randomized trial comparing lung volume reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348:2059-2073.
9. Ram FSF, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2:CD004403.
10. Walters JA, Gibson PG, Wood-Baker R, et al. Systematic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;1:CD001288.
11. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138. Exacerbations become more frequent as COPD progresses.
12. Moullec G, Laurin C, Lavoie KL, et al. Effects of pulmonary rehabilitation on quality of life in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2011, 17:62-71. Rehabilitation provides modest benefits.
13. Niewoehner DE Clinical practice: outpatient management of severe COPD. N Engl J Med 2010, 362:1407-1416. Case-based review.
14. Salvi SS, Barnes PJ Chronic obstructive pulmonary disease in non-smokers. Lancet 2009, 374:733-743. Review emphasizing indoor and outdoor air pollution and occupational exposures.
15. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010, 376:784-793. For the palliative treatment of refractory dyspnea, oxygen therapy is no more effective than room air.
16. Calverley PMA, Anderson JA, Delli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. Randomized trial showing benefit in lung function but not significant benefit for reducing mortality.
17. Casaburi R, ZuWallack R Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 2009, 360:1329-1335. Explanation of the scientific basis for pulmonary rehabilitation and the expected clinical benefits.
18. Cosio MG, Saetta M, Agusti A Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360:2445-2454. Review.
19. Hansel TT, Barnes PJ New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009, 374:744-755. Review.
20. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009, 361:2599-2608. Genetically determined underexpression of MMP12, an alveolar macrophage-derived metalloproteinase implicated in the pathogenesis of centriacinar emphysema, is associated with higher levels of lung function in both children and adults.
21. Sethi S, Murphy TF Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365. Describes role of infection in the pathogenesis of both stable and exacerbated COPD.
22. Wilt TJ, Niewoehner DE, MacDonald R, et al. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med 2007, 147:639-653. Evidence-based review of therapy for stable COPD.